SCHEMBL7326418

SCHEMBL7326418

C#CC1(O)CCN(C(C)=O)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.41
TDP1 Q9NUW8 1/20 0.41
KDM4E B2RXH2 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
USP2 O75604 2/20 0.39
CYP2C9 P11712 5/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
TSHR P16473 2/20 0.38
ALDH1A1 P00352 4/20 0.38
MAPK1 P28482 2/20 0.38
CYP2C19 P33261 2/20 0.38
CYP2D6 P10635 3/20 0.37
CYP3A4 P08684 2/20 0.36
EPHX2 P34913 2/20 0.35
HPGD P15428 1/20 0.35
ALOX12 P18054 1/20 0.35
HSD17B10 Q99714 1/20 0.35
HIF1A Q16665 1/20 0.35
PIK3CD O00329 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4430554 0.81 ALDH1A1 (0.31) ALDH1A1
SCHEMBL28956226 0.79 CYP1A2 (0.41) CYP1A2TDP1KDM4ESMN1; SMN2USP2
SCHEMBL17974981 0.79 OPRM1 (0.41) MEN1KMT2ATSHRALDH1A1EPHX2
SCHEMBL30832133 0.78 SMN1; SMN2 (0.43) CYP1A2TDP1KDM4ESMN1; SMN2ALDH1A1
SCHEMBL17974967 0.78 CYP1A2 (0.40) CYP1A2TDP1KDM4ESMN1; SMN2USP2
SCHEMBL10093511 0.75 CYP1A2 (0.50) CYP1A2TDP1KDM4ESMN1; SMN2USP2
SCHEMBL2110226 0.74 USP2 (0.49) SMN1; SMN2USP2MEN1KMT2ATSHR
SCHEMBL9383218 0.73 SMN1; SMN2 (0.38) CYP1A2TDP1KDM4ESMN1; SMN2USP2
SCHEMBL26381493 0.73 CYP1A2 (0.36) CYP1A2TDP1KDM4ESMN1; SMN2USP2
SCHEMBL992596 0.73 GAA (0.44) ALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4143179-B1 AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS FOR THE TREATMENT OF CANCER IDORSIA PHARMACEUTICALS LTD (CH) 2025-10-22 EP disclosed
US-10202378-B2 Therapeutic compounds and uses thereof GENENTECH, INC. (US) 2019-02-12 US disclosed
US-20180009805-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2018-01-11 US disclosed
WO-2016123391-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2016-08-04 WO disclosed
US-4810792-A HYPOTENSIVE AGENTS HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1989-03-07 US disclosed
US-4788201-A HYPOTENSIVE AGENTS HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1988-11-29 US disclosed
EP-0275962-A2 3-Methylenespiro [benzofuran-piperidines], intermediates and a process for the preparation thereof, and their use as medicaments HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1988-07-27 EP disclosed
EP-0102034-B1 SPIRO(2H-1,4-BENZODIOXEPIN-3(5H)4'-PIPERIDINE AND 3'-PYRROLIDINO) COMPOUNDS, A PROCESS FOR PREPARING THE SAME AND THEIR USE AS MEDICAMENTS HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1988-04-20 EP disclosed
US-4695637-A HYPOTENSIVE AGENTS HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1987-09-22 US disclosed
US-4668791-A HYPOTENSIVE, ALDEHYDES HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1987-05-26 US disclosed
US-4579950-A HYPOTENSIVE AGENTS HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1986-04-01 US disclosed
US-4577026-A HYPOTENSIVE AGENTS HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1986-03-18 US disclosed
US-4569998-A HYPOTENSIVE AGENTS HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1986-02-11 US disclosed
US-4521537-A ANALGESICS HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1985-06-04 US disclosed
US-4472580-A Spiro (2H-1,4-benzodioxepin-3 (5H)4-piperidine and -3-pyrrolidine) compounds and their use as anti-hypertensive agents HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1984-09-18 US disclosed
EP-0102034-A1 Spiro(2H-1,4-benzodioxepin-3(5H)4'-piperidine and 3'-pyrrolidino) compounds, a process for preparing the same and their use as medicaments HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1984-03-07 EP disclosed
US-4405631-A Spiro[2H-1,4-benzodioxepin-3(5H)4'-piperidine and -3'pyrrolidine] compounds and their use as antihypertensive agents HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1983-09-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10202378-B2 Therapeutic compounds and uses thereof TAF1, TAF1L, TAF1B CYP1A2 3656/4885TDP1 53/4885KDM4E 2669/4885
US-20180009805-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF TAF1, TAF1L, TAF1B CYP1A2 3656/4885TDP1 53/4885KDM4E 2669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.